CD274 and neoplasm: After been assessed for human epidermal growth factor receptor 2 (HER2)/neu-negative or HER2/neu positive if previously treated with trastuzumab, PD-L1-positive and DNA mismatch repair tumor status [40], patients received 200 mg of pembrolizumab intravenously every 3 weeks.